SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Ipilimumab
Related studies linked through entity extraction aliases.
A Study to Evaluate the Safety and Efficacy of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Participants With High Grade Primary Central Nervous System (CNS) Malignancies
- Status
- COMPLETED
- Phase
- PHASE2
SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients
- Status
- WITHDRAWN
- Phase
- PHASE2
Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and Nivolumab
- Status
- COMPLETED
- Phase
- PHASE2
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Immunotherapy Study of Evofosfamide in Combination With Ipilimumab
- Status
- UNKNOWN
- Phase
- PHASE1
Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma
- Status
- RECRUITING
- Phase
- PHASE2
Study of Nivolumab Verses Nivolumab and Ipilimumab Combination in EGFR Mutant Non-small Cell Lung Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
- Status
- COMPLETED
- Phase
- PHASE2
Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma
- Status
- COMPLETED
- Phase
- PHASE3
A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer
- Status
- WITHDRAWN
- Phase
- PHASE3
Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma
- Status
- COMPLETED
- Phase
- PHASE2